Treatment history and sampling of studied patients. (A) Twenty-eight samples from 7 patients treated with CD20 bispecs, CD19 CAR T cells, or both sequentially were obtained using ultrasound-guided biopsy. The samples were studied using a comprehensive analytical panel including scRNA-seq, bulk RNA-seq, WES, flow cytometry, and IHC. The analytical panel was adjusted according to the amount and quality of available material. The median of prior lines of therapy before CD20 bispecs and CD19 CAR T cells was 4 (range, 3-6) and 4 (range, 2-7), respectively. (B) Table indicating whether therapy relapse from CD19- and CD20-targeting T-cell–redirecting therapies or tafasitamab (CD19 mAb) was associated with antigen loss (antigen negative) or antigen retainment (antigen positive). Forward-slash indicates that a patient was not treated with the respective therapy or response was not assessable. Allo Tx, allogeneic stem cell transplantation; Auto Tx, autologous stem cell transplantation; BEAM, carmustine, etoposide, cytarabine, and melphalan; Benda, bendamustine; CHOEP, CHOP + etoposide; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; Cis, cisplatin; Dexa, dexamethasone; DHAP, dexamethasone, high-dose cytarabine, and cisplatin; FCM, fludarabine, cyclophosphamide, and mitoxantrone; GemOx, gemcitabine-oxaliplatin; HD, high-dose; ICE, ifosfamide, carboplatin, and etoposide; Ifo, ifosfamide; MTX, methotrexate; O, obinutuzumab; Pola, polatuzumab vedotin; Pred, prednisone; R, rituximab; Rev, lenalidomide (Revlimid); Tafa, tafasitamab; Vin, vincristine.